[go: up one dir, main page]

WO2007017065A3 - Angiogenesis inhibition based upon icam 1 or junb expression levels - Google Patents

Angiogenesis inhibition based upon icam 1 or junb expression levels Download PDF

Info

Publication number
WO2007017065A3
WO2007017065A3 PCT/EP2006/007092 EP2006007092W WO2007017065A3 WO 2007017065 A3 WO2007017065 A3 WO 2007017065A3 EP 2006007092 W EP2006007092 W EP 2006007092W WO 2007017065 A3 WO2007017065 A3 WO 2007017065A3
Authority
WO
WIPO (PCT)
Prior art keywords
determining
subject
methods
disease
test sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/007092
Other languages
French (fr)
Other versions
WO2007017065A2 (en
Inventor
Engeland Manon Van
Arjan W Griffioen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MDxHealth SA
Original Assignee
OncoMethylome Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515471A external-priority patent/GB0515471D0/en
Application filed by OncoMethylome Sciences SA filed Critical OncoMethylome Sciences SA
Priority to EP06762692A priority Critical patent/EP1907856A2/en
Publication of WO2007017065A2 publication Critical patent/WO2007017065A2/en
Publication of WO2007017065A3 publication Critical patent/WO2007017065A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for determining angiogenesis associated with a disease in a subject include the steps of, in a suitable test sample, determining expression levels of at least one gene selected from junB and ICAM 1. A statistically significant decrease in, or low level of, expression of one or both of the genes indicates the presence of angiogenesis associated with the disease in the subject. Preferably, the test sample includes endothelial cells. The method may further include determining the expression of THBSl and/or IGFBP3. Methods of determining angiogenesis in a subject may also include determining the level of acetylated histone H3 in the promote region of the IGFBP3 gene in a test sample. Pharmaceutical compositions for use in inhibiting angiogenesis include a DNA methyltransf erase inhibitor together with a pharmaceutically acceptable carrier and are in a form suitable for metronomic dosing. They may alternatively or additionally include a component allowing targeting to endothelial cells. Methods of preventing or inhibiting angiogenesis associated with a disease in a subject involve administering a therapeutically effective amount of a DNA methyltransf erase inhibitor. Treatment regimes, microarrays and screening methods are also described.
PCT/EP2006/007092 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels Ceased WO2007017065A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06762692A EP1907856A2 (en) 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70258205P 2005-07-27 2005-07-27
GB0515471A GB0515471D0 (en) 2005-07-27 2005-07-27 Angiogenesis inhibition
US60/702,582 2005-07-27
GB0515471.1 2005-07-27

Publications (2)

Publication Number Publication Date
WO2007017065A2 WO2007017065A2 (en) 2007-02-15
WO2007017065A3 true WO2007017065A3 (en) 2007-05-24

Family

ID=37546761

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/007092 Ceased WO2007017065A2 (en) 2005-07-27 2006-07-19 Angiogenesis inhibition based upon icam 1 or junb expression levels

Country Status (2)

Country Link
EP (1) EP1907856A2 (en)
WO (1) WO2007017065A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109810A2 (en) 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of predicting high grade gliomas using senescence associated genes
JP6063392B2 (en) * 2010-12-22 2017-01-18 イドゲン アクチエボラグＩｄｏｇｅｎ ＡＢ Composition comprising at least two compounds inducing indoleamine-2,3-dioxygenase (IDO) for treating pain due to autoimmune disorders or organ immune rejection
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
EP4520828A3 (en) * 2016-11-15 2025-07-09 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN109771647A (en) * 2019-01-28 2019-05-21 首都儿科研究所 Application of DNA Methyltransferase Inhibitor in Construction of Neural Tube Deformity Mouse Model

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400806A1 (en) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400806A1 (en) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CHANG Y, S. ET AL: "mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cnacer", ONCOGENE, vol. 23, 12 July 2004 (2004-07-12), pages 6569 - 6580, XP002425230 *
HELLEBREKERS DEBBY M E I ET AL: "Angiostatic activity of DNA methyltransferase inhibitors.", MOLECULAR CANCER THERAPEUTICS. FEB 2006, vol. 5, no. 2, February 2006 (2006-02-01), pages 467 - 475, XP002413140, ISSN: 1535-7163 *
HELLEBREKERS DEBBY M E I ET AL: "Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications.", CANCER RESEARCH 15 NOV 2006, vol. 66, no. 22, 15 November 2006 (2006-11-15), pages 10770 - 10777, XP002413139, ISSN: 0008-5472 *
KIM M S ET AL: "Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 4, April 2001 (2001-04-01), pages 437 - 443, XP002278083, ISSN: 1078-8956 *
SHEIBANI NADER ET AL: "Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells", CANCER LETTERS, vol. 107, no. 1, 1996, pages 45 - 52, XP002413137, ISSN: 0304-3835 *
ST CROIX B ET AL: "Genes expressed in human tumor endothelium", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 289, no. 5482, 18 August 2000 (2000-08-18), pages 1197 - 1292, XP002201336, ISSN: 0036-8075 *
TSUBAKI JUNKO ET AL: "Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells", ENDOCRINOLOGY, vol. 143, no. 5, May 2002 (2002-05-01), pages 1778 - 1788, XP002425229, ISSN: 0013-7227 *
VAN DER VELDEN P A ET AL: "Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 106, no. 4, 10 September 2003 (2003-09-10), pages 472 - 479, XP002389348, ISSN: 0020-7136 *
VILLAR-GAREA ANA ET AL: "Histone deacetylase inhibitors: Understanding a new wave of anticancer agents", INTERNATIONAL JOURNAL OF CANCER, vol. 112, no. 2, 1 November 2004 (2004-11-01), pages 171 - 178, XP002413155, ISSN: 0020-7136 *
YANG QI-WEI ET AL: "Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.", CANCER RESEARCH, vol. 63, no. 19, 1 October 2003 (2003-10-01), pages 6299 - 6310, XP002413138, ISSN: 0008-5472 *
YOHRLING J W ET AL: "EXPRESSION OF NORMAL AND TUMOR ENDOTHELIAL CELL MARKERS IN MOUSE ENDOTHELIAL CELLS IN VITRO AND IN VIVO", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 44, July 2003 (2003-07-01), pages 407 - 408, XP008034731, ISSN: 0197-016X *

Also Published As

Publication number Publication date
WO2007017065A2 (en) 2007-02-15
EP1907856A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
Senft et al. Ubiquitin ligases in oncogenic transformation and cancer therapy
Van der Velden et al. Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development
WO2007112330A3 (en) Compositions and methods for detection, prognosis and treatment of colon cancer
WO2006121991A3 (en) Compositions and methods for detection, prognosis and treatment of breast cancer
EP3552607A3 (en) Imidazopyrazine syk inhibitors
Kim et al. Association of aminoacyl-tRNA synthetases with cancer
WO2005067391A3 (en) Diagnostic test for parkinson's disease
WO2007085497A3 (en) Markers for the prediction of outcome of anthracycline treatment
US20180051344A1 (en) Embryonic isoforms of gata6 and nkx2-1 for use in lung cancer diagnosis
US20200102565A1 (en) Methods for overcoming glucocorticoid resistance and for determining glucocorticoid resistance potential in cancer
Li et al. Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells
WO2007017065A3 (en) Angiogenesis inhibition based upon icam 1 or junb expression levels
Ouyang et al. STIL is upregulated in nasopharyngeal carcinoma tissues and promotes nasopharyngeal carcinoma proliferation, migration and invasion.
Scartozzi et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
Reed-Gitomer Autosomal dominant polycystic kidney disease: genetics, epidemiology, and treatment
Voora et al. Pharmacogenetics of the response to statins
Licitra et al. Biological agents in head and neck cancer
Mahoney et al. X-linked Inhibitor of Apoptosis Protein Expression and Cisplatin Resistance in Ovarian Cancer
Orlowski TARGETING THE PROTEASOME IN CANCER
Moore et al. 178 GENE PROFILING ON THE EFFECTS OF HDL ON ACTIVATED HUMAN MONOCYTES
Stankic et al. 97P the role of id proteins in the induction of tumor-initiating cells during pulmonary colonization of metastatic breast cancer
WO2006116174A3 (en) Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase
Karaca et al. 98P octreotide in combination with docetaxel triggers apoptosis by inducing Sstr2 and Sstr5 levels in human breast cancer cells, mcf-7 and mda-mb-231
Chua et al. The NEUREGULIN1 gene and breast cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006762692

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2006762692

Country of ref document: EP